Vascular Procedures — Americas | NovaPharmaNews

Breaking

Vanda Pharmaceuticals Launches NEREUS (Tradipitant) - First New Motion Sickness Drug in 40+ Years Now Available Takeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency Disease FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Receives Key Diabetes Drug Approval

NewsApr 25, 2026

Haemonetics VASCADE MVP XL Shows Superior Safety Profile in Large-Bore Venous Closure Study

New study demonstrates Haemonetics' VASCADE MVP XL vascular closure system's enhanced safety and efficacy in large-bore venous access procedures.